TAC1 and COVID-19: We demonstrated that orexin A plasma concentrations in COVID-19 patients were strikingly aberrant and that patients who recovered from severe COVID-19 and were discharged from the ICU exhibited elevated substance P plasma concentrations in a 2.5-yr follow-up.